



18 August

Treatment for chondrosarcoma in Li Fraumeni syndrome: what's next?

**Alberto Romano**



I am a resident in Pediatrics at the Catholic University of the Sacred Heart in Rome where I carry out my clinical, research and study activities at the Pediatric Oncology Department. We treat hematological and oncological pediatric patients with standard and high-dose chemotherapy, radiometabolic therapy with MIBG for neuroblastoma, target therapy and immunotherapy.

In the last two decades, the advancement of knowledge and therapeutic possibilities has led to a marked improvement in the survival of patients with pediatric cancer. However, together with the increase in survival, the sequelae of oncological treatments also appeared. For this reason, in the last two years I have paid particular attention to the study of short and long-term oncological sequelae such as deafness, cardiological damage and visual impairment. Moreover, in our institution we study the effects of topical ocular administration of nerve growth factor in patients with optic glioma and severe visual deficit.

**Sandra Strauss**



Sandra Strauss is a Senior Clinical Lecturer and Honorary Consultant Medical Oncologist. Her clinical post is based at University College London Hospital, part of the London Sarcoma Service, one of the largest sarcoma services in Europe. She specialises in the systemic treatment of bone and soft tissue sarcomas in both adults and teenagers.

Sandra began training as a medical oncologist working on the adolescent unit at the Middlesex Hospital where she developed an interest in sarcoma and teenage and young adult (TYA) cancer. She completed a Cancer Research UK Clinical Fellowship to obtain a PhD (University of London) at St Bartholomew's Hospital.

She is the chief investigator and principal investigator for a number of international and national phase I, II and III studies in sarcoma and is leading a national cohort study in osteosarcoma, ICONIC. She chairs the NCRI Sarcoma Clinical Studies Group Bone Subgroup and was recently appointed Chair of the Executive Committee of the European Euro Ewing Consortium (EEC), a pan-European collaboration to improve outcome for patients with Ewing sarcoma.